medigraphic.com
Órgano oficial de la Sociedad Mexicana de Cirugía Dermatológica y Oncológica, AC

2017, Number 1

<< Back Next >>

Dermatología Cosmética, Médica y Quirúrgica 2017; 15 (1)

Use of Methotrexate, Azathioprine and Mofetil Mycophenolate in Dermatology

Saldaña M, Torres-Camacho P, Arellano MMI

Language: Spanish
References: 83
Page: 45-54
PDF size: 337.69 Kb.


ABSTRACT

Immunosuppressant drugs are those capable to inhibit the immune system. In recent decades they have joined dermatologic therapeutic arsenal, allowing to reduce the use of corticosteroids. This article makes a review of the pharmacological properties and different therapeutic indications of the three major immunomodulators used in dermatology: azathioprine, methotrexate and mycophenolate mofetil.


REFERENCES

  1. Gubner R. Effect of “aminopterine” on epithelial tissues, Arch Dermatol Syphiol 1951; 64: 688-99.

  2. Edmundson WF y Guy WB. Treatment of psoriasis with folic acid antagonists, ama Arch Derm 1958; 78: 200-3.

  3. Roenigk Jr HH, Maibach HI y Weinstein GD. Use of methotrexate in psoriasis, Arch Dermatol 1972; 105: 363-5.

  4. Serrano P y Mascaró J. Metotrexato: actualización en el tratamiento de la psoriasis, Piel 2006; 21: 358-63.

  5. Smith K, Daniel Su WP y Muller S. Methotrexate in dermatology, Derm Sinica 1989; 7: 11-8.

  6. Puig L. Metotrexato: novedades terapéuticas, Actas Dermosifiliogr 2014; 105: 583-9.

  7. Kremer JM, Galivan J, Streckfuss A y Kamen B. Methotrexate metabolism analysis in blood and liver of rheumatoid arthritis patients. Association with hepatic folate deficiency and formation of polyglutamates, Arthritis Rheum 1986; 29: 832-5.

  8. Carretero-Hernández G. Metotrexato en psoriasis: ¿es necesaria una dosis de prueba?, Actas Dermosifiliogr 2012; 103: 1-4.

  9. Saurat JH, Stingl G, Dubertret L et al. champion Study Investigators. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (champion), Br J Dermatol 2008; 158: 558-66.

  10. Barker J, Hoffmann M, Wozel G et al. Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (restore1), Br J Dermatol 2011; 165: 1109-17.

  11. Reich K, Langley RG, Papp KA et al. A 52-week trial comparing briakinumab with methotrexate in patients with psoriasis, N Engl J Med 2011; 365: 1586-96.

  12. Heydendael VM, Spuls PI, Opmeer BC et al. Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis, N Engl J Med 2003; 349: 658-65.

  13. West J, Ogston S y Foerster J. Safety and efficacy of methotrexate in psoriasis: a meta-analysis of published trials, plos one 2016; 11(5): e0153740, doi: 10.1371/journal.pone.0153740.

  14. Hammerschmidt M y Mulinari-Brenner F. Efficacy and safety of methotrexate in alopecia areata, An Bras Dermatol 2014; 89: 729-34.

  15. Droitcourt C, Milpied B, Ezzedine K et al. Interest of high-dose pulse corticosteroid therapy combined with methotrexate for severe alopecia areata: a retrospective case series, Dermatology 2012; 224: 369-73.

  16. Lucas P, Bodemer C, Barbarot S et al. Methotrexate in severe childhood alopecia areata: long-term follow-up, Acta Derm Venereol 2016; 96: 102-3.

  17. Villalba L, Hicks JE, Adams EM et al. Treatment of refractory myositis: a randomized crossover study of two new cytotoxic regimens, Arthritis Rheum 1998; 41: 392-8.

  18. Vencovsk J, Jarosová K, Machácek S et al. Cyclosporine a versus methotrexate in the treatment of polymyositis and dermatomyositis, Scand J Rheumatol 2000; 29: 95-102.

  19. Pérez Pelegay J, Charro Martínez L, Grasa Jordán MP y Carapeto Márquez .J. Pitiriasis liquenoide, Med Cutan Iber Lat Am 2007; 35: 167-73.

  20. Romani J, Puig LL, Fernéndez-Filgueras MT y De Moragas JM. Pityriasis lichenoides in children: clinicopathologic review of 22 patients, Pediatr Dermatol 1998; 15: 1-6.

  21. Castellanos-Íñiguez AA y Guevara Gutiérrez E. Pénfigo vulgar, Dermatol Rev Mex 2011; 55: 73-83.

  22. Sánchez-Pérez J y García-Díez A. Pénfigo, Actas Dermosifiliogr 2005; 96: 329-56.

  23. Fuertes de Vega P, Iranzo-Fernández B y Mascaró-Galy JM. Penfigoide ampolloso: guía de manejo práctico, Actas Dermosifiliogr 2014; 105: 328-34.

  24. Carretero G, Puig L, Dehesa L et al. Metotrexato: guía de psoriasis, Actas Dermosifiliogr 2010; 101: 600-13.

  25. Menter A, Korman NJ, Elmets CA et al. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents, J Am Acad Dermatol 2009; 61: 451-85.

  26. Chalmers RJ, Kirby B y Smith A. Replacement of routine liver biopsy by procollagen iii aminopeptide for monitoring patients with psoriasis receiving longterm methotrexate: a multicentre audit and health economic analysis, Br J Dermatol 2005; 152: 443-9.

  27. Maurice PDL, Maddox AJ y Green CA. Monitoring patients on methotrexate: hepatic fibrosis not seen in patients with normal serum assays of aminoterminale peptide of type ii procollagen, Br J Dermatol 2005; 152: 450-7.

  28. Guillaume JC. Méthotrexate dans le psoriasis: les biopsies hépatiques itératives sont-elles encore nécessaires?, Ann Dermatol Venereol 2006; 133: 513-7.

  29. Lanse SB, Arnold GL, Gowans JD y Kaplan MM. Low incidence of hepatotoxicity associated with long-term, low-dose oral methotrexate in treatment of refractory psoriasis, psoriatic arthritis, and rheumatoid arthritis. An acceptable risk/benefit ratio, Dig Dis Sci 1985; 30: 104-9.

  30. Aithal GP, Haugk B, Das S et al. Monitoring methotrexate-induced hepatic fibrosis in patients with psoriasis: are serial liver biopsies justified?, Aliment Pharmatol Ther 2004; 19: 391-9.

  31. Carrión J. Utilidad del Fibroscan® para evaluar la fibrosis hepática, Gastroenterol Hepatol 2009; 32: 415-23.

  32. Mendoza J, Gómez-Domínguez E y Moreno-Otero R. Elastografía de transición (Fibroscan®), un nuevo método no invasivo en la valoración de la fibrosis hepática, Med Clin Barc 2006; 126: 220-1.

  33. Barbero-Villares A, Mendoza J, Trapero-Marugan M et al. Evaluation of liver fibrosis by transient elastography in methotrexate treated patients, Med Clin Barc 2011; 137: 637-9.

  34. Patel A, Swerlick R y McCall CO. Azathioprine in dermatology: the past, the present, and the future, J Am Acad Dermatol 2006; 55: 369-89.

  35. Wise M y Callen J. Azathioprine: a guide for the management of dermatology patients, Dermatol Therapy 2007; 20: 206-15.

  36. Sanderson J, Ansari A, Marinaki T y Duley J. Thiopurine methyltransferase: should it be measured before commencing thiopurine drug therapy?, Ann Clin Biochem 2004; 41: 294-302.

  37. Szumlanski C, Otterness D, Her C et al. Thiopurine methyltransferase pharmacogenetics: human gene cloning and characterization of a common polymorphism, dna Cell Biol 1996; 15: 17-30.

  38. Schwab M, Schaffeler E y Marx C. Azathioprine therapy and adverse drug reactions in patients with inflammatory bowel disease: impact of thiopurine s-methyltransferase polymorphism, Pharmacogenetics 2002; 12: 429-36.

  39. Jackson AP, Hall AG y McLelland J. Thiopurine methyltransferase levels should be measured before commencing patients on azathioprine, Br J Dermatol 1997; 136: 133-4.

  40. Marra CA, Esdaile JM y Anis AH. Practical pharmacogenetics: the cost effectiveness of screening for thiopurine s-methyltransferase polymorphisms in patients with rheumatological conditions treated with azathioprine, J Rheumatol 2002; 29: 2507-12.

  41. Martel RM, Melwani P, Islas D et al. Safety of azathioprine therapy adjusted to thiopurine methyltransferase activity in the treatment of infantile atopic dermatitis. Report on 7 cases, Actas Dermosifiliogr 2010; 101: 415-20.

  42. Caufield M y Wynnis T. Oral azathioprine for recalcitrant pediatric atopic dermatitis: clinical response and thiopurine monitoring, J Am Acad Dermatol 2013; 68: 29-35.

  43. Roenigk HH Jr y Deodhar S. Pemphigus treatment with azathioprine. Clinical and immunologic correlation, Arch Dermatol 1973; 107: 353-7.

  44. Ljubojevic S, Lipozenci J, Brenner S y Budimci D. Pemphigus vulgaris: a review of treatment over a 19-year period, J Eur Acad Dermatol Venereol 2002; 16: 599-603.

  45. Ahmed AR, Maize JC y Provost TT. Bullous pemphigoid. Clinical and immunologic follow-up after successful therapy, Arch Dermatol 1977; 113: 1043-6.

  46. Greaves MW, Burton JL, Marks J y Dawber RP. Azathioprine in treatment of bullous pemphigoid, Br Med J 1971; 1: 144-5.

  47. Mondino BJ y Brown SI. Immunosuppressive therapy in ocular cicatricial pemphigoid, Am J Ophthalmol 1983; 96: 453-9.

  48. Ginzler E, Sharon E, Diamond H y Kaplan D. Long-term maintenance therapy with azathioprine in systemic lupus erythematosus, Arthritis Rheum 1975; 18: 27-34.

  49. Swaak AJ, Statius van Eps LW, Aarden LA y Feltkamp TE. Azathioprine in the treatment of systemic lupus erythematosus. A three-year prospective study, Clin Rheumatol 1984; 3: 285-91.

  50. Bunch TW, Worthington JW, Combs JJ et al. Azathioprine with prednisone for polymyositis. A controlled, clinical trial, Ann Intern Med 1980; 92: 365-9.

  51. Hafeez Z.H. Unusual presentation of cutaneous vasculitis, Int J Dermatol 1998; 37: 687-90.

  52. Carlson JA, Cavaliere LF y Grant-Kels JM. Cutaneous vasculitis: diagnosis and management, Clin Dermatol 2006; 24: 414-29.

  53. Berth-Jones J, Takwale A, Tan E et al. Azathioprine in severe adult atopic dermatitis: a double-blind, placebo-controlled, crossover trial, Br J Dermatol 2002; 147: 324-30.

  54. Du Vivier A, Munro DD y Verbov J. Treatment of psoriasis with azathioprine, Br Med J 1974; 1: 49-51.

  55. Hacker SM, Ramos-Caro FA, Ford MJ y Flowers FP. Azathioprine: a forgotten alternative for treatment of severe psoriasis, Int J Dermatol 1992; 31: 873-4.

  56. Woolfson H. Acne fulminans with circulating immune complexes and leukaemoid reaction treated with steroids and azathioprine, Clin Exper Dermatol 1987; 12: 463-6.

  57. Hunter GA y Forbes IJ. Treatment of pityriasis rubra pilaris with azathioprine, Br J Dermatol 1972; 87: 42-5.

  58. Lear JT y English JS. Erosive and generalized lichen planus responsive to azathioprine, Clin Exper Dermatol 1996; 21: 56-7.

  59. Calin A. A placebo controlled, crossover study of azathioprine in Reiter’s syndrome, Ann Rheum Dis 1986; 45: 653-5.

  60. Kennedy DT, Hayney MS y Lake KD. Azathioprine and allopurinol: the price of an avoidable drug interaction, Ann Pharmacother 1996; 30: 951-4.

  61. El-Gamel A, Evans C y Keevil B. Effect of allopurinol on the metabolism of azathioprine in heart transplant patients, Transplant Proc 1998; 30: 1127-9.

  62. Cummins D, Sekar M, Halil O y Banner N. Myelosuppression associated with azathioprine–allopurinol interaction after heart and lung transplantation, Transplantation 1996; 61: 1661-2.

  63. Dewit O, Vanheuverzwyn R, Desager JP y Horsmans Y. Interaction between azathioprine and aminosalicylates: an in vivo study in patients with Crohn’s disease, Aliment Pharmacol Ther 2002; 16: 79-85.

  64. Gossmann J, Kachel HG, Schoeppe W y Scheuermann EH. Anemia in renal transplant recipients caused by concomitant therapy with azathioprine and angiotensin-converting enzyme inhibitors, Transplantation 1993; 56: 585-9.

  65. Bradley PP, Warden GD, Maxwell JG y Rothstein G. Neutropenia and thrombocytopenia in renal allograft recipients treated with trimethoprim- sulfamethoxazole, Ann Intern Med 1980; 93: 560-2.

  66. Jones JJ y Ashworth J. Azathioprine-induced shock in dermatology patients, J Am Acad Dermatol 1993; 29: 795-6.

  67. Gardiner SJ y Begg EJ. Pharmacogenetics testing for drug metabolizing enzymes: is it happening in practice?, Pharmacogen Genomics 2005; 15: 365-9.

  68. Hadda V, Pandey BD, Gupta R y Goel A. Azathioprine induced pancytopenia: a serious complication, J Postgrad Med 2009; 55: 139-40.

  69. Sinico RA, Sabadini E, Borlandelli S et al.. Azathioprine hypersensitivity: report of two cases and review of the literature, J Nephrol 2003; 16: 272-6.

  70. Nero P, Rahman A. e Isenberg DA. Does long term treatment with azathioprine predispose to malignancy and death in patients with systemic lupus erythematosus?, Ann Rheum Dis 2004; 63: 325-6.

  71. Silman AJ, Petrie J, Hazleman B y Evans SJ. Lymphoproliferative cancer and other malignancy in patients with rheumatoid arthritis treated with azathioprine: a 20-year follow-up study, Ann Rheum Dis 1988; 47: 988-92.

  72. Robles AL, De la O M y Reynoso J. Clinical pharmacology and therapeutic drug monitoring of immunosuppressive agents, en T Rath (ed), Current Issues and Future Direction in Kidney Transplantation, InTech, Croacia, 2013, pp. 309-42.

  73. Rathee P, Chaudhary H, Rathee S et al. Immunosupressants: a review, Pharma Innovation 2013; 1: 90-9.

  74. Allevato M y Donatti L. Mofetil micofenolato, Act Terap Dermatol 2006; 29: 222.

  75. Mydlarski PR. Mycophenolate mofetil: a dermatologic perspectiva, Skin Therapy Letter 2005; 10: 6.

  76. Strathie SJ y Tait C. Mycophenolic acid in dermatology a century after its discovery, Australas J Dermatol 2015; 56: 77-83.

  77. Lynch WS y Roenigk HH. Mycophenolic acid for psoriasis, Arch Dermatol 1977; 113: 1203-8.

  78. Linn Jones E, Epinette WW, Hackney VC. et al. Treatment of psoriasis with oral mycophenolic acid, J Invest Dermatol 1975; 65: 537-42.

  79. Gómez EC, Menéndez L y Frost P. Efficacy of mycophenolic acid for the treatment of psoriasis, J Am Acad Dermatol 1979; 1: 531-7.

  80. Liu V y Mackool BT. Mycophenolate in dermatology, J Dermatol Treat 2003; 14: 203-11.

  81. Orvis AK, Wesson SK, Breza TS. et al. Mycophenolate mofetil in dermatology, J Am Acad Dermatol 2009; 60: 183-99.

  82. Beissert S, Werfel T y Frieling U. A comparison of oral methyprednisolone plus azathioprine or mycophenolate mofetil for the treatment of bullous pemphigoid, Arch Dermatol 2007; 143: 1536-42.

  83. Martin LK, Werth VP, Villanueva EV y Murrel D. A systematic review of randomized controlled trials for pemphigus vulgaris and pemphigus foliaceus, J Am Acad Dermatol 2010; 64: 903-8.




2020     |     www.medigraphic.com